Herbert Newton, MD

BOARD-CERTIFIED NEURO-ONCOLOGIST AND NEUROLOGIST

Focuses on brain and spinal cord tumors along with their complications, including epilepsy
Herbert Newton, MD

Dr. Newton is a board-certified neuro-oncologist and neurologist with more than 30 years of highly specialized experience treating cancer patients. His primary focus is on the diagnosis and skilled medical care of adult and adolescent patients with tumors of the brain and spinal cord, as well as on the complications of brain tumors – particularly epilepsy. Dr. Newton specializes in the use of chemotherapy and molecular therapeutics, and he is an acclaimed authority in his field with more than 200 published works within scientific journals and medical textbooks. He has been recognized by U.S. News & World Report as one of America’s Top Doctors and is a former Chairman of the American Academy of Neurology Section on Neuro-Oncology.

A graduate of the SUNY Buffalo Medical School, Dr. Newton completed his residency training at the University of Michigan Medical Center in Ann Arbor and undertook his advanced fellowship training in neuro-oncology at Memorial Sloan-Kettering Cancer Center in New York. He joined the Florida Hospital network from the Wallace-Kettering Neuroscience Institute in Ohio, where he served as Director of Neuro-Oncology. Dr. Newton is a Retired Professor of Neurology & Neurosurgery at Ohio State University Medical Center/James Cancer Hospital.

Specialties

  • Adolescent Neuro-Oncology
  • Adult Neuro-Oncology
  • Brain and Spinal Tumors
  • Chemotherapy
  • Epilepsy
  • Metastatic Brain Tumors
  • Molecular Therapeutics
  • CNS Lymphoma

Awards & Honors

  • Listed, America’s Top Doctors, Newsweek, 17 consecutive years
  • Listed, The Best Doctors in America, 17 consecutive years
  • Listed, 2000 Eminent Scientists of Today
  • Spirit of Hope Award, James Cancer Hospital

Research

  • A prospective, multi-center trial of Novo-TTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM
  • Principle Investigator, Phase II Trial of dose intensive temozolomide in combination with Erlotinib (Tarceva) for patients with recurrent malignant astrocytomas
  • Principle Investigator, Analysis of the effect of hypomethylating agents ont eh status of MGMT methylation/expression and response to cytotoxic chemotherapy in glioma cell lines
  • Co-Principal Investigator, A Phase I/II study of anti-angiogenesis therapy for recurrent or progressed atypical and/or unresectable meningiomas
  • Principle Investigator, Retrospective Analysis of the Efficacy and Tolerability of Levitiracetam for the Treatment of Seizures in Patients with Metastatic Brain Tumors

Publications

  • Newton HB: Intra-arterial chemotherapy of primary brain tumors. Current Treat Options Oncol 6, 519-530, 2005
  • Newton HB, Goldlust S, Pearl D:  Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neuro-Oncol 78, 99-102, 2006
  • Newton HB:  Hydroxyurea chemotherapy for meningiomas. Neurosurg Focus 23, E11, 2007
  • Newton HB:  Glioblastoma multiforme.  Curr Treat Options Neurol 10, 285-294, 2008
  • Newton HB:  Bevacizumab.  Review of development, pharmacology, and application to brain tumors.  Clin Med Therapeut 1, 1577-1597, 2009
  • Newton HB:  Overview of angiogenesis and the use of bevacizumab in patients with malignant gliomas. Curr Signal Transduction Ther 8, 25-35, 2013
  • Chowdhary S, Ryken R, Newton HB.  Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas:  Meta-analysis.  J Neuro-Oncol 2015;122:367-382
  • Newton HB, Malkin MG.  Neurological Complications of Systemic Cancer and Antineoplastic Therapy.  Informa Healthcare Publishers, New York, 2010Malkin MG.  Neurological Complications of Systemic Cancer and Antineoplastic Therapy.  Informa Healthcare Publishers, New York, 2010
  • Newton HB, Maschio M.  Epilepsy & Brain Tumors.  Elsevier Medical Publishers, London, 2015
  • Newton HBHandbook of Neuro-Oncology Neuro-Imaging, 2nd Edition.  Elsevier Medical Publishers/Academic Press 2016

Points of Difference

  • Award-Winning Innovations
  • Care, Support and Spa Services
  • Clinical Trials
  • Destination Services
  • National Accreditations and Certifications
  • Nationally Ranked Cancer Programs

Results & Outcomes

  • Higher-than-Average Survival Rate
  • Advanced Diagnostics and Surgical Innovations
  • High Patient Satisfaction
  • Ongoing Research
  • Publications and Presentations
  • Ongoing Data, Results and Comparisons
(407) 603-3800